Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6W8V5)

Drug Name
Lisdexamfetamine Drug Info
Synonyms NRP104; Lisdexamfetamine (INN); Vyvanse (TN)
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Binge eating disorder Approved [2]
Cross-matching ID
PubChem CID
11597698
ChEBI ID
CHEBI:135925
CAS Number
CAS 608137-32-2
TTD Drug ID
DM6W8V5
VARIDT Drug ID
DR00003
INTEDE Drug ID
DR0963
ACDINA Drug ID
D00369

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Trace amine-associated receptor-1 (TAAR1) TTIU98M TAAR1_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID Highest Status REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Approved [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Approved [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Peptide transporter 1 (SLC15A1) DTP PEPT1 3.807 4.52 5.285 7.133
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 3.307 5.005 3.921 5.327
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Attention deficit hyperactivity disorder
ICD Disease Classification 6A05.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Trace amine-associated receptor-1 (TAAR1) DTT TAAR1 6.12E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7213).
2 Lisdexamfetamine FDA Label
3 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
4 Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27.
5 Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.